Get the Stockscreener App
3.8501
3.87%
-0.1549
Molecular Partners Ag Adr stock is traded at $3.8501, with a volume of 3,270.
It is down -3.87% in the last 24 hours and down -24.88% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
See More
Previous Close:
$4.005
Open:
$3.87
24h Volume:
3,270
Relative Volume:
0.73
Market Cap:
$144.04M
Revenue:
$786.00K
Net Income/Loss:
$-73.94M
P/E Ratio:
-1.9405
EPS:
-1.9841
Net Cash Flow:
$-60.81M
1W Performance:
-10.44%
1M Performance:
-24.88%
6M Performance:
+3.79%
1Y Performance:
+1.08%
1-Day Range:
$3.8401
$4.07
1-Week Range:
$3.71
$4.20
52-Week Range:
$3.36
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.8501 | 144.04M | 786.00K | -73.94M | -60.81M | -1.9841 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9% - MarketBeat
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewswire Inc.
HC Wainwright Brokers Increase Earnings Estimates for MOLN - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential By Investing.com - Investing.com South Africa
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com
Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Molecular Partners (NASDAQ: MOLN) outlines DARPin pipeline and cash into 2028 - Stock Titan
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? - TradingView
Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday - Defense World
Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5%Should You Sell? - MarketBeat
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Yahoo Finance
Research Analysts Offer Predictions for MOLN FY2025 Earnings - Defense World
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Molecular Partners stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Molecular Partners stock initiated with Buy rating at H.C. Wainwright - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update - MarketBeat
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1%Here's What Happened - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $3.75 by Analysts at JPMorgan Chase & Co. - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Down 2.2%What's Next? - MarketBeat
EBITDA per share of Molecular Partners AG Sponsored ADR – TRADEGATE:6ML0 - TradingView
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners AG (MOLNZ.XC) Stock Price, News, Quote & History - Yahoo
Liminatus Pharma (LIMN) Short Interest Ratio and Volume 2025 - MarketBeat
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners to cut workforce by a quarter - Reuters
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com Nigeria
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Molecular Partners (MOLN) Stock Trends and Sentiment 2025 - MarketBeat
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting By Investing.com - Investing.com South Africa
Skye Bioscience (SKYE) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
MIRA Pharmaceuticals (MIRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Stock Market News Today - Stock Titan
Stock Ratings and Recommendations: Understanding Analyst Ratings - MarketBeat
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Acrivon Therapeutics (ACRV) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
What is the current Price Target and Forecast for Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - novartis.com
Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners - Reuters
Molecular Partners (MOLN) 10K Form and SEC Filings 2025 - MarketBeat
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):